Abstract: The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques. The invention can be used to indicate the pathologic mechanism, severity of the disease, and treatment response of a subject. The invention can also be used to identify subjects who require more aggressive therapeutic interventions or alternative treatments.

Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.

Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor and a prostanoid. The therapeutic formulations of the disclosure can inhibit cell growth and proliferation and target the underlying pathology of PAH.

Abstract: The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques. The invention can be used to indicate the pathologic mechanism, severity of the disease, and treatment response of a subject. The invention can also be used to identify subjects who require more aggressive therapeutic interventions or alternative treatments.

Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.

Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.

Abstract: Disclosed herein are compounds, compositions, methods and formulations therefor, for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic formulations described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.

Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Abstract: The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques. The invention can be used to indicate the pathologic mechanism, severity of the disease, and treatment response of a subject. The invention can also be used to identify subjects who require more aggressive therapeutic interventions or alternative treatments.

Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating diseases associated with protein kinase activity. The therapeutic indications described herein relate to receptor tyrosine kinase (RTK) inhibition for the treatment or prevention of vascular conditions and proliferative disorders. The disclosure also relates to irreversible RTK inhibitors.

Abstract: Systems and methods for neutralizing a solution comprising a compound of interest, comprising: aerosolizing a solution, wherein the solution is a low pH solution and comprises the compound of interest; contacting the aerosolized solution with ammonia vapor, wherein the ammonia vapor neutralizes at least a portion of said aerosolized solution; and removing at least some water from the neutralized aerosolized solution, wherein the neutralized aerosolized solution is at least partially dehydrated.

Abstract: Systems and methods for neutralizing a solution comprising a compound of interest, comprising: aerosolizing a solution, wherein the solution is a low pH solution and comprises the compound of interest; contacting the aerosolized solution with ammonia vapor, wherein the ammonia vapor neutralizes at least a portion of said aerosolized solution; and removing at least some water from the neutralized aerosolized solution, wherein the neutralized aerosolized solution is at least partially dehydrated.

Abstract: The present invention relates to a method of treating pulmonary arterial hypertension by administering a therapeutically effective amount of a selective JAK2 inhibitor to a patient in need thereof.